Compare KMT & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KMT | ANIP |
|---|---|---|
| Founded | 1938 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 1.9B |
| IPO Year | 1994 | 1999 |
| Metric | KMT | ANIP |
|---|---|---|
| Price | $29.54 | $72.64 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 8 | 9 |
| Target Price | $31.43 | ★ $105.78 |
| AVG Volume (30 Days) | ★ 1.2M | 295.9K |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | ★ 2.70% | N/A |
| EPS Growth | 268.33 | ★ 419.23 |
| EPS | ★ 4.42 | 2.32 |
| Revenue | ★ $2,356,698,000.00 | $206,547,000.00 |
| Revenue This Year | $43.37 | $24.85 |
| Revenue Next Year | $2.98 | $10.76 |
| P/E Ratio | ★ $6.67 | $31.75 |
| Revenue Growth | ★ 19.82 | 2.47 |
| 52 Week Low | $21.70 | $69.58 |
| 52 Week High | $43.81 | $96.57 |
| Indicator | KMT | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 38.50 | 49.08 |
| Support Level | $28.97 | $69.88 |
| Resistance Level | $31.15 | $83.03 |
| Average True Range (ATR) | 0.94 | 1.92 |
| MACD | -0.25 | 0.18 |
| Stochastic Oscillator | 14.35 | 62.27 |
Kennametal Inc is a manufacturer of metalworking tools and wear-resistant engineered components and coatings. The company operates in two business segments; Metal Cutting and Infrastructure. It generates maximum revenue from the Metal Cutting segment. The Metal Cutting segment develops and manufactures high-performance tooling and metal cutting products and services and offers an assortment of standard and custom metal cutting solutions to diverse end markets, including aerospace, general engineering, energy, and transportation. Geographically, it derives maximum revenue from the United States and the rest from Germany, China, Canada, India, Italy, and other countries.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.